Professional Summary
Education & Certifications
- Fellowship: Cleveland Clinic Foundation (2015) OH
- Fellowship: Cleveland Clinic Foundation (2012) OH
- Board Certification: American Board of Internal Medicine, Medical Oncology (2023)
-
- Board Certification: American Board of Internal Medicine, Medical Oncology (2012)
- Residency: Harbor UCLA Internal Medicine Residency (2009) CA
- Medical Education: The Ohio State University Registrar (2006) OH
Administrative Appointments
- Associate Director, Cancer Research Training and Education, Stanford Cancer Institute (2025 - Present)
- Associate Program Director, Hematology and Oncology Fellowship, Stanford University (2024 - Present)
- Co-Director, Immunotherapy Toxicity Program, Stanford University (2023 - Present)
-
- Co-Director, Skin Cancer Genomics Program, Stanford University (2023 - Present)
Publications
-
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials
Jeter, J. M., Bowles, T. L., Curiel-Lewandrowski, C., Swetter, S. M., Filipp, F. V., Abdel-Malek, Z. A., … Cassidy, P. B. (2019). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. CANCER, 125(1), 18–44. -
Germline predisposition in oncologic and dermatologic melanoma cohorts.
Funchain, P., Ni, Y., Bungo, B., Heald, B., Arbesman, M., Behera, T. R., … Arbesman, J. (2022). Germline predisposition in oncologic and dermatologic melanoma cohorts. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
ss-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma
Switzer, B., Pandey, M. R., Valentine, A., Witkiewicz, A., Knudsen, E., Attwood, K., … Gandhi, S. (2022). ss-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
-
Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth, R., Agarwala, S. S., Messersmith, H., Alluri, K. C., Ascierto, P. A., Atkins, M. B., … Weber, J. (2023). Systemic Therapy for Melanoma: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2301136. -
Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
Liu, C., Shatila, M., Mathew, A., Machado, A. P., Thomas, A., Zhang, H. C., … Wang, Y. (2023). Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer. Journal of Cancer, 14(10), 1913–1919. -
Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality.
Yan, C., Huang, M., Swetlik, C., Toljan, K., Mahadeen, A. Z., Bena, J., … McGinley, M. (2023). Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality. European Journal of Neurology. -
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
El Zarif, T., Nassar, A. H., Adib, E., Fitzgerald, B. G., Huang, J., Mouhieddine, T. H., … Naqash, A. R. (2023). Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 41(21), 3712–3723. -
Melanoma body site distribution: Germline genetics may have a lesser role.
Decosma, L., Ni, Y., Funchain, P., & Arbesman, J. (2023). Melanoma body site distribution: Germline genetics may have a lesser role. JAAD International, 11, 220–221. -
Reincarnating autoimmunity: Immune-related adverse events as new diseases.
Funchain, P. (2023). Reincarnating autoimmunity: Immune-related adverse events as new diseases. Cleveland Clinic Journal of Medicine, 90(5), 318–319. -
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.
Orlow, I., Sadeghi, K. D., Edmiston, S. N., Kenney, J. M., Lezcano, C., Wilmott, J. S., … Berwick, M. (2023). InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PloS One, 18(4), e0269324. -
Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.
Farha, N., Faisal, M. S., Allende, D. S., Sleiman, J., Shah, R., Farha, N., … Philpott, J. R. (2023). Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center. The Oncologist, 28(8), 706–713. -
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Unger, J. M., Darke, A., Othus, M., Truong, T.-G. G., Khushalani, N., Kendra, K., … Patel, S. P. (2023). Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncology, 9(2), 251–260. -
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins, M. B., Lee, S. J., Chmielowski, B., Tarhini, A. A., Cohen, G. I., Truong, T.-G. G., … Kirkwood, J. M. (2023). Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 41(2), 186–197. -
Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series.
Longinow, J., Zmaili, M., Skoza, W., Kondoleon, N., Marquardt, R., Calabrese, C., … Moudgil, R. (2023). Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series. Cancer Medicine, 12(3), 2281–2289. -
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.
Rodón, J., Funchain, P., Laetsch, T. W., Arkenau, H.-T. T., Hervieu, A., Singer, C. F., … Delaloge, S. (2022). A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations. Future Oncology (London, England), 18(30), 3377–3387. -
Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.
Sussman, T. A., Knackstedt, R., Wei, W., Funchain, P., & Gastman, B. R. (2022). Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016. Journal for Immunotherapy of Cancer, 10(8). -
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
Sheng, I. Y., Gupta, S., Reddy, C. A., Angelini, D., Funchain, P., Sussman, T. A., … Khorana, A. A. (2022). Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors. Targeted Oncology, 17(5), 563–569. -
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.
Luo, L., Shen, R., Arora, A., Orlow, I., Busam, K. J., Lezcano, C., … Berwick, M. (2022). Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study. Pigment Cell & Melanoma Research, 35(6), 605–612. -
Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report.
Behera, T. R., Song, J. M., Ko, J., Eicher, D., Arbesman, J., Gastman, B., … Funchain, P. (2022). Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report. Frontiers in Oncology, 12, 846187. -
Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.
Seth, R., Messersmith, H., & Funchain, P. (2022). Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 40(21), 2375–2377. -
Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival.
Alomari, M., Al Ashi, S., Chadalavada, P., Khazaaleh, S., Covut, F., Al Momani, L., … Romero-Marrero, C. (2022). Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival. Gastroenterology Research, 15(2), 56–66. -
A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients.
Li, C., Phoon, Y. P., Karlinsey, K., Tian, Y. F., Thapaliya, S., Thongkum, A., … Gastman, B. R. (2022). A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. The Journal of Experimental Medicine, 219(1). -
Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma.
Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., … Ribas, A. (2022). Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discovery, 12(3), 644–653. -
Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
Sheng, I. Y., Gupta, S., Reddy, C. A., Angelini, D., Funchain, P., Sussman, T. A., … Khorana, A. A. (2021). Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. Targeted Oncology, 16(6), 813–821. -
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., … Bollin, K. (2021). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(36), 4073–4126. -
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Santomasso, B. D., Nastoupil, L. J., Adkins, S., Lacchetti, C., Schneider, B. J., Anadkat, M., … Ghosh, M. (2021). Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(35), 3978–3992. -
Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms.
Rikhi, R., Karnuta, J., Hussain, M., Collier, P., Funchain, P., Tang, W. H., … Moudgil, R. (2021). Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms. Frontiers in Cardiovascular Medicine, 8, 721333. -
Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
Sleiman, J., Wei, W., Shah, R., Faisal, M. S., Philpott, J., & Funchain, P. (2021). Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study. Journal for Immunotherapy of Cancer, 9(6). -
Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.
Roopkumar, J., Swaidani, S., Kim, A. S., Thapa, B., Gervaso, L., Hobbs, B. P., … Khorana, A. A. (2021). Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. Med (New York, N.Y.), 2(4), 423–434. -
Clinical Trials in Metastatic Uveal Melanoma: Current Status.
Sussman, T. A., Funchain, P., & Singh, A. (2020). Clinical Trials in Metastatic Uveal Melanoma: Current Status. Ocular Oncology and Pathology, 6(6), 381–387. -
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman, T. A., Li, H., Hobbs, B., Funchain, P., McCrae, K. R., & Khorana, A. A. (2021). Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. Journal for Immunotherapy of Cancer, 9(1). -
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Gandhi, S., Pandey, M. R., Attwood, K., Ji, W., Witkiewicz, A. K., Knudsen, E. S., … Ernstoff, M. S. (2021). Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 27(1), 87–95. -
Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study.
Klek, S., Heald, B., Milinovich, A., Ni, Y., Abraham, J., Mahdi, H., … Funchain, P. (2020). Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study. JNCI Cancer Spectrum, 4(3), pkaa018. -
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar, Y. G., Navrazhina, K., Ding, F., Bhatia, R., Tsai, K., Abbate, K., … Shoushtari, A. (2020). Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. Journal for Immunotherapy of Cancer, 8(1). -
CMV coinfection in treatment refractory immune checkpoint inhibitor colitis.
Harris, K. B., Funchain, P., & Baggott, B. B. (2020). CMV coinfection in treatment refractory immune checkpoint inhibitor colitis. BMJ Case Reports, 13(5). -
Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database.
Conic, R. R., Knackstedt, R., Sussman, T. A., Rambhia, S., Damiani, G., Funchain, P., … Gastman, B. R. (2020). Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database. Melanoma Research, 30(4), 376–385. -
Targeted next generation sequencing (NGS) to classify melanocytic neoplasms.
Zarabi, S. K., Azzato, E. M., Tu, Z. J., Ni, Y., Billings, S. D., Arbesman, J., … Ko, J. S. (2020). Targeted next generation sequencing (NGS) to classify melanocytic neoplasms. Journal of Cutaneous Pathology, 47(8), 691–704. -
Systemic Therapy for Melanoma: ASCO Guideline.
Seth, R., Messersmith, H., Kaur, V., Kirkwood, J. M., Kudchadkar, R., McQuade, J. L., … Funchain, P. (2020). Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 38(33), 3947–3970. -
Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels.
Akras, Z., Bungo, B., Leach, B. H., Marquard, J., Ahluwalia, M., Carraway, H., … Funchain, P. (2019). Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels. JCO Precision Oncology, 3, 1–11. -
Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes.
Xu, L. T., Funchain, P. F., Bena, J. F., Li, M., Tarhini, A., Berber, E., & Singh, A. D. (2019). Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes. Ocular Oncology and Pathology, 5(5), 323–332. -
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
Abu-Sbeih, H., Ali, F. S., Naqash, A. R., Owen, D. H., Patel, S., Otterson, G. A., … Wang, Y. (2019). Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 37(30), 2738–2745. -
Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes.
Erstine, E. M., Tetzlaff, M. T., Jia, X., Aung, P. P., Prieto, V. G., Funchain, P., … Ko, J. S. (2019). Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes. The American Journal of Surgical Pathology. -
The Microbiome of Temporal Arteries.
Hoffman, G. S., Getz, T. M., Padmanabhan, R., Villa-Forte, A., Clifford, A. H., Funchain, P., … Eng, C. (2019). The Microbiome of Temporal Arteries. Pathogens & Immunity, 4(1), 21–38. -
Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node positivity and association with overall survival.
Conic, R. R., Ko, J., Saridakis, S., Damiani, G., Funchain, P., Vidimos, A., & Gastman, B. R. (2019). Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node positivity and association with overall survival. Journal of the American Academy of Dermatology, 81(2), 364–372. -
Immune Check Point Inhibitor-Associated Glomerulonephritis.
Ashour, T., Nakhoul, G., Patil, P., Funchain, P., & Herlitz, L. (2019). Immune Check Point Inhibitor-Associated Glomerulonephritis. Kidney International Reports, 4(2), 355–359. -
Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience.
Sadaps, M., Funchain, P., Mahdi, H., Grivas, P., Pritchard, A., Klek, S., … Sohal, D. P. (2018). Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. JCO Precision Oncology, 2, 1–11. -
Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.
Patil, P. D., Fernandez, A. P., Velcheti, V., Tarhini, A., Funchain, P., Rini, B., … Pennell, N. A. (2019). Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. The Oncologist, 24(1), 4–8. -
Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma.
Ko, J. S., Gastman, B. R., Conic, R., Tellez Diaz Trujillo, A., Diaz-Montero, C. M., Billings, S. D., … Atanaskova Mesinkovska, N. (2019). Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma. The American Journal of Dermatopathology, 41(3), 180–187. -
Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.
Conic, R. R., Ko, J., Damiani, G., Funchain, P., Knackstedt, T., Vij, A., … Gastman, B. R. (2019). Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database. Journal of the American Academy of Dermatology, 80(2), 441–447. -
How should we diagnose and manage checkpoint inhibitor-associated colitis?
Khan, F., Funchain, P., Bennett, A., Hull, T. L., & Shen, B. (2018). How should we diagnose and manage checkpoint inhibitor-associated colitis? Cleveland Clinic Journal of Medicine, 85(9), 679–683. -
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Johnson, D. B., Bordeaux, J., Kim, J. Y., Vaupel, C., Rimm, D. L., Ho, T. H., … Dakappagari, N. (2018). Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 24(21), 5250–5260. -
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.
Sun, L., Funchain, P., Song, J. M., Rayman, P., Tannenbaum, C., Ko, J., … Gastman, B. (2018). Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. Journal for Immunotherapy of Cancer, 6(1), 36. -
Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations.
Arbesman, J., Ravichandran, S., Funchain, P., & Thompson, C. L. (2018). Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell & Melanoma Research, 31(4), 529–533. -
Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma.
Stiegel, E., Xiong, D., Ya, J., Funchain, P., Isakov, R., Gastman, B., & Vij, A. (2018). Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma. Journal of the American Academy of Dermatology, 78(5), 942–948. -
Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha, R., Miller, J. A., Venur, V. A., Mohammadi, A. M., Chao, S. T., Suh, J. H., … Ahluwalia, M. S. (2018). Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. Journal of Neurosurgery, 129(1), 50–59. -
Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas.
Wang, H., Funchain, P., Bebek, G., Altemus, J., Zhang, H., Niazi, F., … Eng, C. (2017). Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas. Genome Medicine, 9(1), 14. -
Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma.
Mukherjee, P. K., Funchain, P., Retuerto, M., Jurevic, R. J., Fowler, N., Burkey, B., … Ghannoum, M. A. (2017). Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma. BBA Clinical, 7, 8–15. -
Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients.
Ragin, C., Liu, J. C., Jones, G., Shoyele, O., Sowunmi, B., Kennett, R., … Taioli, E. (2017). Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients. Carcinogenesis, 38(2), 218–229. -
Strategies for clinical implementation of screening for hereditary cancer syndromes.
Heald, B., Marquard, J., & Funchain, P. (2016). Strategies for clinical implementation of screening for hereditary cancer syndromes. Seminars in Oncology, 43(5), 609–614. -
Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.
Hong, S., Funchain, P., Haddad, A., Crowe, J., Dalpiaz, N., & Abraham, J. (2016). Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations. Journal of Oncology Practice, 12(3), 270–2. -
Prospective Clinical Study of Precision Oncology in Solid Tumors.
Sohal, D. P., Rini, B. I., Khorana, A. A., Dreicer, R., Abraham, J., Procop, G. W., … Bolwell, B. J. (2015). Prospective Clinical Study of Precision Oncology in Solid Tumors. Journal of the National Cancer Institute, 108(3). -
Hunting for cancer in the microbial jungle.
Funchain, P., & Eng, C. (2013). Hunting for cancer in the microbial jungle. Genome Medicine, 5(5), 42. -
MC1R signaling through the cAMP-CREB/ATF-1 and ERK-NF?B pathways accelerates G1/S transition promoting breast cancer progression.
Chelakkot, V. S., Thomas, K., Romigh, T., Fong, A., Li, L., Ronen, S., … Arbesman, J. (2023). MC1R signaling through the cAMP-CREB/ATF-1 and ERK-NF?B pathways accelerates G1/S transition promoting breast cancer progression. NPJ Precision Oncology, 7(1), 85. -
Clinical and Immunologic Features of Germline Pathogenic Variant (gPV) Positive Patients with Melanoma.
Shen, A., Arbesman, M., Lodha, R., Rayman, P., Bungo, B., Ni, Y., … Funchain, P. (2023). Clinical and Immunologic Features of Germline Pathogenic Variant (gPV) Positive Patients with Melanoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Real-world experience of talimogene laherparepvec in patients receiving immunotherapy in metastatic melanoma.
Behera, T. R., Song, J. M., Ko, J. S., McNamara, M. J., Funchain, P., & Gastman, B. (2020). Real-world experience of talimogene laherparepvec in patients receiving immunotherapy in metastatic melanoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Patterns in progression from early stage melanoma to late stage melanoma: Implications for survivorship follow up.
Switzer, B., Savage, D. J., Song, J. M., Stanek, C., & Funchain, P. (2020). Patterns in progression from early stage melanoma to late stage melanoma: Implications for survivorship follow up. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness.
Sussman, T. A., Wei, W., Hobbs, B., Diaz-Montero, C. M., Ni, Y., Arbesman, J., … Funchain, P. (2020). A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Role of glutamine metabolism in CD8<SUP>+</SUP>PD-1<SUP>+</SUP>TIM-3<SUP>+</SUP> T cells in ICI resistant melanoma.
Thapaliya, S., Gastman, B., Phoon, Y. P., Li, C., Zhou, B., Funchain, P., … Cameron, C. (2020). Role of glutamine metabolism in CD8+PD-1+TIM-3+ T cells in ICI resistant melanoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
INCIDENCE OF THROMBOEMBOLISM (TE) IN PATIENTS WITH MELANOMA RECEIVING IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY AND ITS ADVERSE IMPACT ON SURVIVAL
Sussman, T., Roopkumar, J., Li, H., McCrae, K., Funchain, P., & Khorana, A. (2020). INCIDENCE OF THROMBOEMBOLISM (TE) IN PATIENTS WITH MELANOMA RECEIVING IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY AND ITS ADVERSE IMPACT ON SURVIVAL. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
OUTCOMES OF STAGE IV MELANOMA IN THE ERA OF IMMUNOTHERAPY: A NATIONAL CANCER DATABASE (NCDB) ANALYSIS
Sussman, T., Wei, W., Funchain, P., & Gastman, B. (2020). OUTCOMES OF STAGE IV MELANOMA IN THE ERA OF IMMUNOTHERAPY: A NATIONAL CANCER DATABASE (NCDB) ANALYSIS. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
SURVIVAL OUTCOMES AND TOXICITY AMONG PATIENTS TREATED WITH CONCOMITANT RADIOTHERAPY AND IMMUNOTHERAPY FOR ADVANCED MELANOMA: TWO FACES OF THE ABSCOPAL EFFECT?
Andreatos, N., Roopkumar, J., Khorana, A., Woody, N., Gastman, B., & Funchain, P. (2020). SURVIVAL OUTCOMES AND TOXICITY AMONG PATIENTS TREATED WITH CONCOMITANT RADIOTHERAPY AND IMMUNOTHERAPY FOR ADVANCED MELANOMA: TWO FACES OF THE ABSCOPAL EFFECT? JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy
Sheng, I. Y.-F., Gupta, S., Reddy, C. A., Angelini, D. E., Funchain, P., Roopkumar, J., … Khorana, A. A. (2020). Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy. BLOOD. AMER SOC HEMATOLOGY. -
Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report From a Major Tertiary Care Center
Faisal, M. S., Sleiman, J., Shah, R. S., Funchain, P., & Philpott, J. (2020). Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report From a Major Tertiary Care Center. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Immune-mediated adverse events following concomitant radiotherapy and immunotherapy in patients with melanoma and Merkel cell carcinoma: A preliminary report from an evolving retrospective registry.
Andreatos, N., Roopkumar, J., Khorana, A. A., & Funchain, P. (2020). Immune-mediated adverse events following concomitant radiotherapy and immunotherapy in patients with melanoma and Merkel cell carcinoma: A preliminary report from an evolving retrospective registry. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Thromboembolism (TE) in patients (pts) with bladder cancer treated with checkpoint inhibitors (CPIs).
Sheng, I. Y.-F., Gupta, S., Reddy, C. A., Angelini, D. E., Funchain, P., Sussman, T. A., … Khorana, A. A. (2020). Thromboembolism (TE) in patients (pts) with bladder cancer treated with checkpoint inhibitors (CPIs). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Increased normal tissue telomere length is associated with decreased survival in melanoma patients
Ni, Y., Romigh, T., Funchain, P., & Arbesman, J. (2020). Increased normal tissue telomere length is associated with decreased survival in melanoma patients. JOURNAL OF INVESTIGATIVE DERMATOLOGY. ELSEVIER SCIENCE INC. -
SINGLE CELL TRANSCRIPTOME ANALYSIS IDENTIFIES UNIQUE FEATURES IN CIRCULATING CD8+T CELLS THAT CAN PREDICT IMMUNOTHERAPY RESPONSE IN MELANOMA PATIENTS
Li, C., Phoon, Y. P., Karlinsey, K., Tian, Y., Thapaliya, S., Qu, L., … Gastman, B. (2020). SINGLE CELL TRANSCRIPTOME ANALYSIS IDENTIFIES UNIQUE FEATURES IN CIRCULATING CD8+T CELLS THAT CAN PREDICT IMMUNOTHERAPY RESPONSE IN MELANOMA PATIENTS. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Prognosis of patients developing immune-related adverse events with immune checkpoint inhibitors in melanoma influenced by the ability to resume therapy
Song, J. M., Behera, T. R., Demski, K., Yurco, A., Patil, P. D., & Funchain, P. (2020). Prognosis of patients developing immune-related adverse events with immune checkpoint inhibitors in melanoma influenced by the ability to resume therapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Venous thromboembolism (VTE) in melanoma patients (pts) on immunotherapy (IO)
Sussman, T. A., Roopkumar, J., Li, H., Hobbs, B., Khorana, A. A., & Funchain, P. (2020). Venous thromboembolism (VTE) in melanoma patients (pts) on immunotherapy (IO). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Immune Checkpoint Inhibitor Related Colitis (ICI-Colitis) in Patients With Preexisting Inflammatory Bowel Disease or Microscopic Colitis
Sleiman, J., Shah, R., Wei, W., Funchain, P., Philpott, J., & Simons-Linares, R. (2019). Immune Checkpoint Inhibitor Related Colitis (ICI-Colitis) in Patients With Preexisting Inflammatory Bowel Disease or Microscopic Colitis. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES
Lauko, A., Ali, A., Sagar, S., Barnett, A., Li, H., Chao, S., … Ahluwalia, M. (2019). IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
Variations of Diagnosis and Management of Immune Checkpoint Inhibitor Pancreatic Injury (ICIPI) and Immune Checkpoint Inhibitor Pancreatitis: A Single Institution Experience
Shah, R., Sleiman, J., Simons-Linares, R., Faisal, M., Song, J.-M., Philpott, J., & Funchain, P. (2019). Variations of Diagnosis and Management of Immune Checkpoint Inhibitor Pancreatic Injury (ICIPI) and Immune Checkpoint Inhibitor Pancreatitis: A Single Institution Experience. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Immune Checkpoint Inhibitors-Related Gastrointestinal Toxicity Is Associated With Better Overall Survival and Treatment Response in Cancer Patients
Alomari, M., Al Ashi, S., Al Momani, L., Nehme, F., Sarmini, M. T., Young, M., … Romero-Marrero, C. (2019). Immune Checkpoint Inhibitors-Related Gastrointestinal Toxicity Is Associated With Better Overall Survival and Treatment Response in Cancer Patients. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade
Swaidani, S., Roopkumar, J., Jun-Shim, Y., Charles, C., Paul, S., Kundu, S., … McCrae, K. R. (2019). Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade. BLOOD. AMER SOC HEMATOLOGY. -
Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases
Knackstedt, R., Sussman, T. A., McCahon, L., Song, J.-M., Funchain, P., & Gastman, B. (2019). Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases. ANNALS OF ONCOLOGY, 30(8), 1399–1400. -
Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.
Diaz-Montero, C. M., Ravichandran, S., Pavicic, P. G., Rayman, P. A., Tannenbaum, C., Finke, J., … Tarhini, A. A. (2019). Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer
Sadaps, M., Funchain, P., Heald, B., Huether, R., Pitt, J., White, K., … Sohal, D. (2019). A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.
Conces, M., Ni, Y., Bazeley, P., Patel, B., Funchain, P., & Carraway, H. E. (2019). Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.
Abu-Sbeih, H., Ali, F., Naqash, A. R., Owen, D. H., Patel, S. H., Otterson, G. A., … Wang, Y. (2019). Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).
Thapa, B., Roopkumar, J., Kim, A. S., Gervaso, L., Patil, P. D., Calabrese, C., … Funchain, P. (2019). Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Comparison of head and neck and nonehead and neck Merkel cell carcinoma: Clinicopathologic characteristics, time to treatment initiation, and survival
Conic, R., Ko, J., Damiani, G., Funchain, P., Vidimos, A., & Gastman, B. (2019). Comparison of head and neck and nonehead and neck Merkel cell carcinoma: Clinicopathologic characteristics, time to treatment initiation, and survival. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. MOSBY-ELSEVIER. -
Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node utilization, positivity and effects on overall survival
Conic, R., Ko, J., Damiani, G., Funchain, P., Vidimos, A., & Gastman, B. (2019). Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node utilization, positivity and effects on overall survival. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. MOSBY-ELSEVIER. -
Immune Checkpoint Inhibitors Associated with Cardiotoxicity in Cancer Patients: A Large Single-Center Experience
Chahine, J., Thapa, B., Ala, C. K., Patil, P., Funchain, P., Maroo, A., … Tang, W. H. W. (2019). Immune Checkpoint Inhibitors Associated with Cardiotoxicity in Cancer Patients: A Large Single-Center Experience. JOURNAL OF CARDIAC FAILURE. CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS. -
The paradox of melanoma in oculocutaneous albinism: A case report and literature review
Ravichandran, S., Funchain, P., & Arbesman, J. (2019). The paradox of melanoma in oculocutaneous albinism: A case report and literature review. JOURNAL OF INVESTIGATIVE DERMATOLOGY. ELSEVIER SCIENCE INC. -
THE MICROBIOME OF TEMPORAL ARTERIES
Hoffman, G. S., Getz, T. M., Padmanabhan, R., Villa-Forte, A., Calabrese, L. H., Clifford, A. H., … Eng, C. (2019). THE MICROBIOME OF TEMPORAL ARTERIES. RHEUMATOLOGY. OXFORD UNIV PRESS. -
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials (vol 125, pg 18, 2019)
Jeter, J. M., Bowles, T. L., Curiel-Lewandrowski, C., Swetter, S. M., Filipp, F. V., Abdel-Malek, Z. A., … Cassidy, P. B. (2019). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials (vol 125, pg 18, 2019). CANCER, 125(15), 2706. -
Posterior Reversible Encephalopathy Syndrome during Treatment with Lenvatinib
Khoury, J., & Funchain, P. (2018). Posterior Reversible Encephalopathy Syndrome during Treatment with Lenvatinib. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The Impact of a Novel Immune Related Adverse Event Tumor Board on Interprofessional Clinical Confidence and Collaboration
Calabrese, C., Funchain, P., Patil, P. D., & Calabrese, L. H. (2018). The Impact of a Novel Immune Related Adverse Event Tumor Board on Interprofessional Clinical Confidence and Collaboration. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Shared medical appointment for early stage melanoma survivorship
Funchain, P., Song, J. M., Stanek, C., McNamara, M. J., Tarhini, A. A., Gastman, B., & Marcus, J. D. (2018). Shared medical appointment for early stage melanoma survivorship. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes
Mendiratta, P., Loehr, A., Simmons, A., Barata, P. C., Klek, S., Pritchard, A., … Grivas, P. (2018). Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic.
Sadaps, M., Funchain, P., Mahdi, H., Grivas, P., Pritchard, A., Klek, S., … Sohal, D. (2018). Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Multiplex germline testing in selected melanomas presenting to oncology clinic
Funchain, P., Heald, B., Song, J. M., Nizialek, E., Marquard, J., McNamara, M. J., … Arbesman, J. (2018). Multiplex germline testing in selected melanomas presenting to oncology clinic. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB).
Klek, S., Heald, B., Milinovich, A., Ni, Y., Abraham, J., Grivas, P., … Funchain, P. (2018). Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Germline variants from paired somatic-germline testing in pancreatic cancer.
Funchain, P., Heald, B., White, K., Buschmann, M., Roggin, K. K., Khorana, A. A., & Sohal, D. (2018). Germline variants from paired somatic-germline testing in pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Single center experience of dermatologic and oncologic surveillance patterns for late stage melanomas that progressed from early stage melanoma.
Song, J. M., Marcus, J. D., Stanek, C., McNamara, M. J., Gastman, B., Tarhini, A. A., & Funchain, P. (2018). Single center experience of dermatologic and oncologic surveillance patterns for late stage melanomas that progressed from early stage melanoma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Using Genomic Sequencing to Improve Management in Melanoma
Funchain, P., & Tarhini, A. A. (2018). Using Genomic Sequencing to Improve Management in Melanoma. ONCOLOGY-NEW YORK, 32(3), 98-+. -
Outcomes Following Spine Stereotactic Radiosurgery for the Treatment of Melanoma Spine Metastases
Tom, M. C., Yang, K., Balagamwala, E. H., Angelov, L., Mohammadi, A. M., McNamara, M., … Chao, S. T. (2017). Outcomes Following Spine Stereotactic Radiosurgery for the Treatment of Melanoma Spine Metastases. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Precision oncology experience at a tertiary care center.
Sadaps, M., Funchain, P., Grivas, P., Estfan, B. N., Abraham, J., Stevenson, J., … Sohal, D. (2017). Precision oncology experience at a tertiary care center. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
Sun, L., Funchain, P., Song, J.-M., McNamara, M., & Gastman, B. (2017). Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC. -
Changing Treatment Paradigms for Brain Metastases From Melanoma PART 2: When and How to Use the N.ew Systemk Agents
Venur, V. A., Funchain, P., Kotecha, R., Chao, S. T., & Ahluwalia, M. S. (2017). Changing Treatment Paradigms for Brain Metastases From Melanoma PART 2: When and How to Use the N.ew Systemk Agents. ONCOLOGY-NEW YORK, 31(9), 659–667. -
Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance
Barata, P. C., Koshkin, V. S., Funchain, P., Sohal, D., Pritchard, A., Klek, S., … Grivas, P. (2017). Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. ANNALS OF ONCOLOGY, 28(10), 2458–2463. -
Changing Treatment Paradigms for Brain Metastases From Melanoma
Venur, V. A., Funchain, P., Kotecha, R., Chao, S. T., & Ahluwalia, M. S. (2017). Changing Treatment Paradigms for Brain Metastases From Melanoma. ONCOLOGY-NEW YORK, 31(8), 602–606. -
Single-center experience of PD1 inhibition in metastatic uveal melanoma.
Xu, T., Song, J. M., McNamara, M. J., Gastman, B., Singh, A. D., & Funchain, P. (2017). Single-center experience of PD1 inhibition in metastatic uveal melanoma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Flow cytometric detection of MDSC populations in unfractionated blood.
Diaz-Montero, C. M., Rayman, P. A., Kim, J. S., Pavicic, P. G., Tannenbaum, C., Velcheti, V., … Finke, J. (2017). Flow cytometric detection of MDSC populations in unfractionated blood. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Do patients learn from survivorship care plans?
Bodmann, J., Harr, B. A., Rybicki, L. A., Koyfman, S. A., Geiger, J. L., Funchain, P., … Adelstein, D. J. (2017). Do patients learn from survivorship care plans? JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Clinical predictive factors of overall survival and locoregional failure in advanced laryngeal cancer treated with definitive chemoradiation.
Khan, A. M., Ward, M. C., Adelstein, D. J., Koyfman, S. A., Reddy, C. A., Bhateja, P., … Nwizu, T. I. (2016). Clinical predictive factors of overall survival and locoregional failure in advanced laryngeal cancer treated with definitive chemoradiation. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Comprehensive Functional Genomic Profiling of HPV Unassociated Head and Neck Squamous Cell Cancer Identifies Neomorphic Mutations That Confer Resistance to Therapy
Kittel, J., Funchain, P., Chute, D., Woody, N. M., Hammerman, P., Koyfman, S., & Abazeed, M. (2015). Comprehensive Functional Genomic Profiling of HPV Unassociated Head and Neck Squamous Cell Cancer Identifies Neomorphic Mutations That Confer Resistance to Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Clinical Predictors of Locoregional Failure in Advanced Laryngeal Cancer Treated With Definitive Chemotherapy and Radiation
Khan, A. M., Ward, M. C., Adelstein, D. J., Koyfman, S., Reddy, C. A., Bhateja, P., … Nwizu, T. (2016). Clinical Predictors of Locoregional Failure in Advanced Laryngeal Cancer Treated With Definitive Chemotherapy and Radiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Prospective clinical study of precision oncology in solid tumors
Sohal, D., Rini, B. I., Khorana, A. A., Dreicer, R., Abraham, J., Procop, G., … Bolwell, B. J. (2015). Prospective clinical study of precision oncology in solid tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Hereditary implications of somatic tumor testing
Funchain, P., Sohal, D., Khorana, A. A., Abraham, J., Pennell, N. A., Rini, B. I., … Eng, C. (2015). Hereditary implications of somatic tumor testing. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Temporal Artery Microbiome in Giant Cell Arteritis.
Clifford, A., Funchain, P., Lystad, L., Peterson, C., Altemus, J., Hoffman, G. S., & Eng, C. (2014). Temporal Artery Microbiome in Giant Cell Arteritis. ARTHRITIS & RHEUMATOLOGY. WILEY-BLACKWELL. -
Microbiomes of Inflammatory and Non-Inflammatory Thoracic Aortic Aneurysms.
Funchain, P., Hoffman, G. S., Svensson, L., Roselli, E., Pettersson, G., Johnston, D., … Eng, C. (2014). Microbiomes of Inflammatory and Non-Inflammatory Thoracic Aortic Aneurysms. ARTHRITIS & RHEUMATOLOGY. WILEY-BLACKWELL. -
A reinvestigation of somatic hypermethylation at the <i>PTEN</i> CpG island in cancer cell lines
Hesson, L. B., Packham, D., Pontzer, E., Funchain, P., Eng, C., & Ward, R. L. (2012). A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines. BIOLOGICAL PROCEDURES ONLINE, 14, 5. -
Correlation of microbiomic profiles with disease status and <i>MDR1</i> methylation in head and neck squamous cell carcinoma (HNSCC).
Funchain, P., Bebek, G., Bennett, K. L., Burkey, B., & Eng, C. (2012). Correlation of microbiomic profiles with disease status and MDR1 methylation in head and neck squamous cell carcinoma (HNSCC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma
Bebek, G., Bennett, K. L., Funchain, P., Campbell, R., Seth, R., Scharpf, J., … Eng, C. (2012). Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Microbiomic subprofiles and <i>MDR1</i> promoter methylation in head and neck squamous cell carcinoma
Bebek, G., Bennett, K. L., Funchain, P., Campbell, R., Seth, R., Scharpf, J., … Eng, C. (2012). Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma. HUMAN MOLECULAR GENETICS, 21(7), 1557–1565. -
Acute liver injury induced by weight-loss herbal supplements
Chen, G. C., Ramanathan, V. S., Law, D., Funchain, P., Chen, G. C., French, S., … Pham, B. (2010). Acute liver injury induced by weight-loss herbal supplements. WORLD JOURNAL OF HEPATOLOGY, 2(11), 410–415. -
Mutants with temperature-sensitive defects in the <i>Escherichia coli</i> mismatch repair system:: Sensitivity to mispairs generated in vivo
Hong, E. S., Yeung, A., Funchain, P., Slupska, M. M., & Miller, J. H. (2005). Mutants with temperature-sensitive defects in the Escherichia coli mismatch repair system:: Sensitivity to mispairs generated in vivo. JOURNAL OF BACTERIOLOGY, 187(3), 840–846. -
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets
Rush, L. J., Raval, A., Funchain, P., Johnson, A. J., Smith, L., Lucas, D. M., … Plass, C. (2004). Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. CANCER RESEARCH, 64(7), 2424–2433. -
In vitro and in vivo studies of MutS, MutL and MutH mutants: correlation of mismatch repair and DNA recombination
Junop, M. S., Yang, W., Funchain, P., Clendenin, W., & Miller, J. H. (2003). In vitro and in vivo studies of MutS, MutL and MutH mutants: correlation of mismatch repair and DNA recombination. DNA REPAIR, 2(4), 387–405. -
Aberrant DNA methylation in chronic lymphocytic leukemia: A role in pathogenesis?
Raval, A., Rush, L. J., Funchain, P., Flak, E., Davis, M., Johnson, A. J., … Plass, C. (2002). Aberrant DNA methylation in chronic lymphocytic leukemia: A role in pathogenesis? BLOOD. AMER SOC HEMATOLOGY. -
<i>Escherichia coli</i> strains (<i>ndk</i>) lacking nudeoside diphosphate kinase are powerful mutators for base substitutions and frameshifts in mismatch-repair-deficient strains
Miller, J. H., Funchain, P., Clendenin, W., Huang, T., Nguyen, A., Wolff, E., … Yang, H. J. (2002). Escherichia coli strains (ndk) lacking nudeoside diphosphate kinase are powerful mutators for base substitutions and frameshifts in mismatch-repair-deficient strains. GENETICS, 162(1), 5–13. -
Amplification of mutator cells in a population as a result of horizontal transfer
Funchain, P., Yeung, A., Stewart, J., Clendenin, W. M., & Miller, J. H. (2001). Amplification of mutator cells in a population as a result of horizontal transfer. JOURNAL OF BACTERIOLOGY, 183(12), 3737–3741. -
The consequences of growth of a mutator strain of <i>Escherichia coli</i> as measured by loss of function among multiple gene targets and loss of fitness
Funchain, P., Yeung, A., Stewart, J. L., Lin, R., Slupska, M. M., & Miller, J. H. (2000). The consequences of growth of a mutator strain of Escherichia coli as measured by loss of function among multiple gene targets and loss of fitness. GENETICS, 154(3), 959–970. -
Temporary and Permanent,Mutators lacking the mismatch repair system: The enhancement of mutators in cell populations
Miller, J. H., Yeung, A., Funchain, P., Mao, E., Stewart, J., Clendenin, W. M., & Slupska, M. M. (2000). Temporary and Permanent,Mutators lacking the mismatch repair system: The enhancement of mutators in cell populations. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY. COLD SPRING HARBOR LAB PRESS. -
Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma
Kirane, A., Lee, D., Ahmad, M. U., Sharma, S., Serasanambati, M., Lowe, M., … Maverakis, E. (2024). Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma. ANNALS OF SURGICAL ONCOLOGY. SPRINGER. -
Germline Cancer Susceptibility in Individuals with Melanoma.
Funchain, P., Ni, Y., Heald, B., Bungo, B., Arbesman, M., Behera, T. R., … Arbesman, J. (2024). Germline Cancer Susceptibility in Individuals with Melanoma. Journal of the American Academy of Dermatology. -
Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon, Y. P., Lopes, J. E., Pfannenstiel, L. W., Marcela Diaz-Montero, C., Tian, Y. F., Ernstoff, M. S., … Gastman, B. R. (2024). Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics. Journal for Immunotherapy of Cancer, 12(4). -
Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies
Dima, D., Lopetegui-Lia, N., Ogbue, O., Osantowski, B., Ullah, F., Jia, X., … Funchain, P. (2024). Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies. CANCER MEDICINE, 13(12). -
TripleMoverlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database
Naqash, A. R., Abushukair, H. M., Alghamdi, E., Laharwal, M. M., Gundroo, H. M., Tan, A.-choon, … Al-Harbi, F. F. (2024). TripleMoverlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Long-term cardiovascular outcomes of immune checkpoint inhibitor-related myocarditis: A large single-centre analysis.
Braghieri, L., Gharaibeh, A., Nkashama, L., Abushouk, A., Abushawer, O., Mehdizadeh-Shrifi, A., … Moudgil, R. (2024). Long-term cardiovascular outcomes of immune checkpoint inhibitor-related myocarditis: A large single-centre analysis. ESC Heart Failure. -
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.
Conway, K., Edmiston, S. N., Vondras, A., Reiner, A., Corcoran, D. L., Shen, R., … Thomas, N. E. (2024). DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precision Oncology, 8, e2400375. -
Retrospective analysis of immunotherapy outcomes in Black patients.
Reynolds, K. L., & Funchain, P. (2024). Retrospective analysis of immunotherapy outcomes in Black patients. The Lancet. Oncology. -
How Many Doses of Infliximab Should Be Used in Immune Checkpoint Inhibitor-Induced Colitis? - A Retrospective Study
Kundu, R., Chatterjee, A., Zabor, E., Isaacs, J., Truong, T.-G., Sleiman, J., … Kennedy, L. (2024). How Many Doses of Infliximab Should Be Used in Immune Checkpoint Inhibitor-Induced Colitis? - A Retrospective Study. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Germline Pathogenic Variant (gPV) Positive Patients with Melanoma Exhibit Improved Response to Checkpoint Inhibitor Immunotherapy.
Shen, A., Arbesman, M., Lodha, R., Rayman, P., Gastman, B., Ko, J., … Arbesman, J. (2025). Germline Pathogenic Variant (gPV) Positive Patients with Melanoma Exhibit Improved Response to Checkpoint Inhibitor Immunotherapy. The Journal of Investigative Dermatology. -
Patterns in progression from early-stage melanoma to late-stage melanoma: implications for survivorship follow-up.
Savage, D. J., Switzer, B., Parikh, R., Song, J. M., Stanek, C., Arbesman, J., … Funchain, P. (2024). Patterns in progression from early-stage melanoma to late-stage melanoma: implications for survivorship follow-up. Melanoma Management, 11(1), 2424708. -
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.
Nassar, A. H., Abou Alaiwi, S., El Zarif, T., Denu, R., Macaron, W., Abdel-Wahab, N., … Naqash, A. R. (2025). Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal for Immunotherapy of Cancer, 13(3). -
Genetic Landscape of Mucosal Melanoma: Identifying Pathogenic Germline Variants.
Ribaudo, I., Arbesman, M., Ni, Y., Isaacs, J., Kennedy, L. B., Ko, J., … Arbesman, J. (2025). Genetic Landscape of Mucosal Melanoma: Identifying Pathogenic Germline Variants. Pigment Cell & Melanoma Research, 38(2), e70007. -
Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open.
Joshi, U. M., Hundal, J., Mata, J. R., Schollenberger, M. D., Warrier, G., Luke, J. J., … Funchain, P. (2025). Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 45(3), e473856. -
Proceedings of the seventh annual Women in Melanoma Conference.
Najjar, Y. G., Orloff, M., Mitchell, T. C., Bowles, T. L., Betof Warner, A., Bollin, K., … Patel, S. P. (2025). Proceedings of the seventh annual Women in Melanoma Conference. Therapeutic Advances in Medical Oncology, 17, 17588359251342039. -
Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy.
Shatila, M., Devalaraju, S., Takigawa, K., Catinis, C., Lee, I., Baerman, E., … Wang, Y. (2025). Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy. Journal of the National Comprehensive Cancer Network : JNCCN, 1–7. -
Germline Pathogenic Variants (gPVs) and Immune-Related Adverse Events (IRAEs) in Patients with Melanoma Receiving Immune Checkpoint Inhibitors (ICI).
Shen, A., Arbesman, M., Newell, D., Chen, J., Arbesman, J., Funchain, P., & Kennedy, L. B. (2025). Germline Pathogenic Variants (gPVs) and Immune-Related Adverse Events (IRAEs) in Patients with Melanoma Receiving Immune Checkpoint Inhibitors (ICI). Journal of the American Academy of Dermatology. -
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
Zhu, L., Cheung, Y.-M. M., Chiang, C., Gallagher, E. J., Hamnvik, O.-P. R., Mammen, J., … Shariff, A. (2025). Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors. Journal for Immunotherapy of Cancer, 13(10). -
Tumor microRNA signatures associate with stage II/III melanoma patient outcomes.
Wiggins, J. M., Zhang, Q., Zhang, Y., Vand-Rajabpour, F., Hanniford, D., He, L., … Hernando, E. (2025). Tumor microRNA signatures associate with stage II/III melanoma patient outcomes. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model.
Phoon, Y. P., Wolfarth, A. A., Funchain, P., Ko, J. S., Choi, D., Dedkova, E., … Gastman, B. R. (2025). NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model. Scientific Reports, 15(1), 37950. -
Cutaneous melanocytic mosaicism with associated melanoma: A case series.
Ribaudo, I., Aldosari, E., Funchain, P., Paragh, G., Wickenheiser, M., & Arbesman, J. (2026). Cutaneous melanocytic mosaicism with associated melanoma: A case series. JAAD Case Reports, 68, 191–198. -
Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) discussed at a multidisciplinary immune-related adverse event (irAE) tumor board.
Vandommelen, K., Brihn, L., Calabrese, C., Zhou, K., Smith, M., Abdoh, M., … Kennedy, L. B. (2025). Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) discussed at a multidisciplinary immune-related adverse event (irAE) tumor board. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Seasons of risk: Investigating temporal trends in ICI-associated Myocarditis
Griffith, C., Park, E., Cheng, E., Mccroskey, S., Katsumoto, T., Zhu, H., & Funchain, P. (2026). Seasons of risk: Investigating temporal trends in ICI-associated Myocarditis. CANCER IMMUNOLOGY RESEARCH. AMER ASSOC CANCER RESEARCH. -
Chronic sequelae of immune-related adverse events.
Ngo, S., Rong, J., Menon, R., Colli Cruz, C., Chatterjee, A., Mortan, R., … Wang, Y. (2026). Chronic sequelae of immune-related adverse events. Expert Opinion on Drug Safety.
-
Systemic Therapy for Melanoma: ASCO Guideline Update.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Skin Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Skin Cancer Program in Palo Alto
900 Blake Wilbur Dr, 3rd Fl
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Review Summary
Dr. Funchain is described as knowledgeable and thorough, with an emphasis on clear communication. Many appreciate that she explains information in detail and ensures understanding. Several patients highlight her caring and compassionate nature. She is seen as personable and professional, taking time to discuss issues completely.
The summary was created by AI, based on recent patient reviews. Learn more
Was this result useful to you?
Patient Reviews
(56 reviews)
She is extremely knowledgeable
thank you
The doctor seems like a highly intelligent and analytical person with a warm heart. I believe she truly wants me to get better in this study.
As I mentioned before Dr Funchain is an excellent doctor, she has taken care of me and my melanoma diagnosis for the past two years and I have nothing but high praise for her. Her nurse Lisa has also been outstanding with making sure my appointments are made and accommodating my schedule.
This space isn’t big enough to praise Dr.Funchain and her expert care which always comes with such professionalism. I just really am happy she is my doctor.Simply the best!!!
Very professional and helpful!
Dedicated oncologist
Please see previous comments.
She was great.
Excellent!
Very professional!
Dr. Pauline Funchain is very friendly with a nice smile and personality and knowledgeable about the subject and specific issues that I'm dealing with medically.
Very informative.
simply great !!!
Dr Funchain is an excellent doctor and has provided me outstanding care for my stage three melanoma, she is very intelligent and knows her stuff. She has always taken her time with me at each visit and goes over my scans with meticulous expertise. I am very fortunate to have her as my heath care provider. I have been seeing her for over a year and half and never had a bad visit. Thank you Dr. Funchain!
She was friendly and explained in detail everything.â ¤ï¸
She is a great doctor and thank you for working with me 👠☺ï¸
Doctor Funchain and staff are Fun-tastic.
She is very kind and excellent in explaining things and answering questions
Very professional and answered all our questions
Dr. Funchain was very helpful. Enjoyed the visit.
excellent communication, very personable
She is an excellent doctor and very thorough in every aspect of my visits.
She was very knowledgeable, sympathetic and a good listener, very patiently answering all my questions.
Great team collaboration
Dr. Pauline Funchain is very caring about her patients health.
She and her staff are friendly, helpful and knowledgeable. ….it’s a pleasure to deal with them.
Dr Pauline Funchain stay's aware of the progress of my treatment and keeps me informed.
She is the best of the best - helpful, involved, informative, gracious and confident.
My guardian angel.
she is my rock
She is great - very knowledgeable and very curious as well as helpful.
Dr. Funchain was very informative. I felt she explained things so that I understood and listened to my wishes regarding my care.
Dr. Funchain was very detailed about all the information I wanted. Thank you.
she is the best
She was very responsive, however some answers were inconsistent from prior answers which was a bit confusing.
She and her stuff work hard to get me through this crisis 😊
Very articulate, personable and thorough. Excellent physician.!
I had a great video visit with Dr Funchain! Dr is very knowledgeable & thoroughly communicated in regards to my health and future treatments.
Excellent. Took necessary time to discuss issues very completely. Much appreciated. Excellent doctor.
Listens well and follows through
Dr. Funchain is an extremely personable, professional and thoughtful physician. I feel very lucky to have her as my doctor.
Dr Funchain and her entire team are excellent. I would highly recommend her and her team to anyone in need of caring, compassionate, through health care
Dr. Funchain and her assisting staff are very accommodating about changes between live visits and video visits. They are also helpful in making referrals to other doctors within the Stanford network.
Dr Funchain is the best, she explains everything in detail, she answers all of my questions, and spends the time to make sure that we have the proper steps going forward with my treatments. Also, her nurse Lisa always stays in touch and makes sure I have everything I need for blood test orders and upcoming appointments. Lisa is kind and compassionate as is Dr Funchain. I have been very please with my health care with both of them.
She is so sweet and caring young lady. I appreciate her interest in my illness.
Very competent and helpful
Dr. Funchain is very professional and takes her time to explain everything in detail and goes over every lab so that I can understand it.
He nurse Lisa is very good and get the next appointments going as soon as we hang up the video appointment.
She has always been cheerful and positive about my treatment. She truly tries to make me feel better.
Very personal and caring.
Dr Funchain was very thorough explaining everything about my cancer and laid out a plan to continue my treatment
Excellent to work with
Dr Funchain is very much to the point so it is easy to understand what is trying to transmit.
Excellent. Informative, listens well, knowledgeable, compassionate
She is very technically competent, easy to understand and I am lucky to have her as my "go-to" doctor at Stanford.
Excellent and helpful
The best
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records